4 min read
Peptides: The Less-is-More Strategy for Success
By Jennifer Somera on 05/06/2021
A strategic approach to peptide design yields success
When deciding which antigens to use for an antibody discovery project, there are many available options. Peptides, which have been around for at least 60 years, are one way in. Other — and, in many cases, newer — available paths include recombinant proteins, engineered cells and DNA coding for the protein.
Topics: News Insights SARS-CoV-2 antibody discovery peptides
1 min read
Original Research: Generating Antibodies to SARS-CoV-2 Spike Protein Sites
By Dr. John Kenney on 01/19/2021
As we’ve noted in some recent blog posts (here and here, for instance), our team at Antibody Solutions is joining the global scientific community in the collective fight against SARS-CoV-2 and its mutations. That includes both research conducted on behalf of our clients and our own discoveries.
Topics: News Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
2 min read
The UK Strain and Other Recent RBD Mutations in the SARS-CoV-2 Virus
By Dr. John Kenney on 12/22/2020
Examining mutations in the SARS-CoV-2 Spike (S) Protein Receptor Binding Domain (RBD) at the ACE2 receptor S protein interface
Topics: News Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
6 min read
News Release: Study Identifies Potential COVID Vaccine & Therapy Research Pathways
By Dr. John Kenney on 06/17/2020
Conformational change of the spike protein furin cleavage domain may enhance virus infectivity
June 16, 2020 (Santa Clara, Calif.) — Research by two U.S.-based antibody discovery companies shows a rise and dominance of a mutant SARS-CoV-2 virus and identifies a new mechanism predicting a competitive advantage of the mutation. The mutation is predicted to induce a structural change in the spike protein of the virus that would enhance virus entry. The study, conducted by Antibody Solutions and Single Cell Technology (SCT), is available on Preprints.org (the study’s findings have not yet been peer-reviewed).
Topics: News Covid SARS-CoV-2 Molecuar Modeling COVID-19
1 min read
Antibody Solutions COVID-19 Update #2
By Dr. John Kenney on 04/02/2020
UPDATED 4/2/2020
On March 31, 2020, California Gov. Gavin Newsom extended the statewide shelter-in-place order through May 3, 2020. Additional restrictions designed to help protect citizens from the COVID-19 pandemic also were imposed.
Consistent with the March 19 order, this order considers life science companies such as Antibody Solutions to be “essential,” meaning we are exempt from many restrictions imposed on other businesses and can continue our operations. As specified in this order, we are preparing an updated document formalizing the social distancing protocol we had implemented in accordance with the first order.
Topics: News Covid COVID-19
1 min read
Antibody Solutions COVID-19 Update #1
By Dr. John Kenney on 03/17/2020
UPDATED 3/20/2020
On March 19, 2020, California Gov. Gavin Newsom announced statewide requirements in light of the COVID-19 pandemic. These required actions in this order align with the Santa Clara County shelter-in-place orders released earlier this week and have not imposed any additional restrictions on Antibody Solutions operations. We will continue to monitor this situation and provide updates, as necessary.
On March 16, 2020, the Public Health Department of Santa Clara County, California, along with five other San Francisco Bay Area counties, issued a shelter-in-place order for all county residents in response to the COVID-19 pandemic. That includes us here at Antibody Solutions.
Topics: News Covid COVID-19
3 min read
Come Together, Right Now—For What Could Be
By Dr. John Kenney on 02/06/2020
Antibody Solutions’ Grand Opening Celebration | 01.30.20
From sparkling selfies and twirling mobiles of antibodies to insightful speeches, facility tours and tasty tacos, Antibody Solutions’ Grand Opening celebration last week had a little bit of everything. And we couldn’t be prouder!(*)
More than 125 treasured clients, partners and their families came together for what could be--and was—an evening of fun, festivity and friendship. We held the event to commemorate both our new 33,300-square-foot facility in Santa Clara, Calif., and the kickoff to our Silver Anniversary. The theme for our event was “25 Years of Revealing the Future,” and it was especially wonderful to welcome many guests who’ve been with us through the decades.
Topics: News 25th Anniversary
2 min read
Expanded Partnership Offers Antibody Solutions Clients Access to the Transgenic H2L2 Harbour Mice™ Platform
By Dr. John Kenney on 05/16/2019
Agreement Provides for Easy Access to the Transgenic H2L2 Harbour Mice™ Platform with Antibody Solutions’ Discovery and Development Services
Topics: News Transgenic Animals transgenic H2L2 mice Harbour
2 min read
Antibody Solutions Announces Partnership with SCT at 2017 Antibody Engineering & Therapeutics Conference
By Debra Valsamis on 12/11/2017
Antibody Solutions, a leader in discovery of therapeutic, biomarker and critical reagent antibodies, and Single Cell Technology, Inc. (SCT), a pioneer in single cell analysis technology, have launched a partnership that offers pharmaceutical researchers one-stop access to advanced single B-cell antibody discovery capabilities.
Topics: News
Filter by Keyword
- Insights (32)
- COVID-19 (14)
- Covid (14)
- SARS-CoV-2 (14)
- Events (12)
- Molecuar Modeling (9)
- News (9)
- Transgenic Animals (5)
- antibody discovery (4)
- Therapeutic Targets (3)
- 25th Anniversary (2)
- Omicron (2)
- therapeutic monoclonal antibodies (2)
- ADC (1)
- Antibody-Drug Conjugate (1)
- CAR-T (1)
- Cell therapy (1)
- Functional Assays (1)
- Harbour (1)
- Hybridoma (1)
- IgG purification (1)
- Lambda Mouse (1)
- MAbExpress (1)
- Monoclonal (1)
- OmniRat (1)
- antigen (1)
- cell fusion (1)
- igG (1)
- immunoassays (1)
- immunogens (1)
- lambda light chain (1)
- mRNA (1)
- peptides (1)
- syngeneic (1)
- target analysis (1)
- transgenic H2L2 mice (1)
- women in bio (1)